Gen-Probe launches colon cancer mutation test kit in Europe
This article was originally published in Clinica
Executive Summary
Gen-Probe has launched its Elucigene KRAS.BRAF kit in Europe. The assay is designed to help tailor treatment for colorectal cancer patients, by detecting seven common mutations in the KRAS gene and the V600E mutation in the BRAF gene. Patients with mutations in these genes do not respond to EGFR inhibitor drugs such as Amgen's Vectibix. Elucigene KRAS.BRAF is a single-tube, PCR-based fluorescent assay designed for simplicity and ease of use. It reduces laboratory workload, analysis time and the potential for sample mix-up, San Diego, California-based Gen-Probe claims. The test is not yet cleared in the US.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.